In clinical trials, it has demonstrated significant weight loss effects, leading to its FDA approval for the following indication and usage: WEGOVY is a glucagon-like peptide-1 receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in: adult patients with an initial body mass index of 30 kg/m2 or greater or 27 kg/m2 or greater in the presence of at least one weight-related comorbid condition
GLP-1+GIP dual-agonists - such as tirzepatide - add a second mechanism: mimicking GIP (glucose-dependent insulinotropic polypeptide), which targets additional hormonal pathways involved in appetite and blood sugar regulation
Hadidchi and her team are committed to supporting you at every step, helping you set realistic goals and answering any questions you may have about your progress or potential side effects
Wegovy is FDA-approved for promoting weight loss and reducing the risk of cardiovascular problems such as heart attack, stroke, and cardiovascular death in patients with obesity and overweight when paired with lifestyle modifications such as low-calorie diet and exercise
Whether you're considering a semaglutide prescription online for the first time or switching from compounded medications to FDA-approved drugs, our experienced North Las Vegas team is ready to assist you
